Genertec Universal Medical Group Company Limited

SEHK:2666 Stock Report

Market Cap: HK$9.2b

Genertec Universal Medical Group Valuation

Is 2666 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2666 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2666 (HK$4.79) is trading below our estimate of fair value (HK$10.18)

Significantly Below Fair Value: 2666 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2666?

Key metric: As 2666 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 2666. This is calculated by dividing 2666's market cap by their current earnings.
What is 2666's PE Ratio?
PE Ratio4.1x
EarningsCN¥2.06b
Market CapCN¥8.55b

Price to Earnings Ratio vs Peers

How does 2666's PE Ratio compare to its peers?

The above table shows the PE ratio for 2666 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average10x
3877 CSSC (Hong Kong) Shipping
4.7x7.3%HK$10.0b
6069 SY Holdings Group
27.3x28.1%HK$7.2b
1905 Haitong Unitrust International Financial Leasing
4.4xn/aHK$7.0b
1606 China Development Bank Financial Leasing
3.4x7.9%HK$15.6b
2666 Genertec Universal Medical Group
4.1x6.8%HK$9.2b

Price-To-Earnings vs Peers: 2666 is good value based on its Price-To-Earnings Ratio (4.1x) compared to the peer average (10x).


Price to Earnings Ratio vs Industry

How does 2666's PE Ratio compare vs other companies in the HK Diversified Financial Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
2666 4.1xIndustry Avg. 7.4xNo. of Companies10PE01020304050+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 2666 is good value based on its Price-To-Earnings Ratio (4.1x) compared to the Hong Kong Diversified Financial industry average (7.4x).


Price to Earnings Ratio vs Fair Ratio

What is 2666's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2666 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio4.1x
Fair PE Ratio7.8x

Price-To-Earnings vs Fair Ratio: 2666 is good value based on its Price-To-Earnings Ratio (4.1x) compared to the estimated Fair Price-To-Earnings Ratio (7.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2666 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$4.79
HK$7.05
+47.3%
16.1%HK$8.64HK$6.03n/a3
Dec ’25HK$4.68
HK$7.05
+50.7%
16.1%HK$8.64HK$6.03n/a3
Nov ’25HK$4.96
HK$7.05
+42.2%
16.1%HK$8.64HK$6.03n/a3
Oct ’25HK$5.06
HK$7.05
+39.4%
16.1%HK$8.64HK$6.03n/a3
Sep ’25HK$4.46
HK$7.21
+61.7%
14.8%HK$8.60HK$6.00n/a3
Aug ’25HK$4.37
HK$6.94
+58.8%
18.8%HK$8.55HK$5.36n/a3
Jul ’25HK$4.25
HK$7.01
+64.9%
18.7%HK$8.60HK$5.39n/a3
Jun ’25HK$4.44
HK$7.01
+57.8%
18.7%HK$8.60HK$5.39n/a3
May ’25HK$4.72
HK$6.23
+31.9%
13.3%HK$7.05HK$5.40n/a2
Apr ’25HK$4.27
HK$6.15
+44.0%
15.2%HK$7.08HK$5.22n/a2
Mar ’25HK$4.25
HK$6.15
+44.7%
15.2%HK$7.08HK$5.22n/a2
Feb ’25HK$4.04
HK$7.00
+73.3%
20.3%HK$8.70HK$5.22n/a3
Jan ’25HK$4.49
HK$6.53
+45.4%
19.7%HK$8.56HK$5.13n/a5
Dec ’24HK$4.25
HK$6.53
+53.6%
19.7%HK$8.56HK$5.13HK$4.685
Nov ’24HK$3.95
HK$6.87
+73.9%
17.6%HK$8.55HK$5.13HK$4.964
Oct ’24HK$3.91
HK$7.10
+81.5%
16.2%HK$8.60HK$5.16HK$5.065
Sep ’24HK$4.08
HK$7.10
+73.9%
16.2%HK$8.60HK$5.16HK$4.465
Aug ’24HK$4.20
HK$7.18
+70.9%
15.9%HK$8.56HK$5.18HK$4.375
Jul ’24HK$4.30
HK$7.18
+66.9%
15.9%HK$8.56HK$5.18HK$4.255
Jun ’24HK$4.59
HK$7.70
+67.8%
9.7%HK$8.74HK$6.80HK$4.444
May ’24HK$5.21
HK$7.69
+47.6%
21.3%HK$10.30HK$5.30HK$4.725
Apr ’24HK$4.75
HK$7.69
+62.0%
21.2%HK$10.30HK$5.31HK$4.275
Mar ’24HK$4.62
HK$7.41
+60.5%
23.4%HK$10.07HK$5.24HK$4.254
Feb ’24HK$4.86
HK$7.66
+57.6%
23.2%HK$10.30HK$5.36HK$4.044
Jan ’24HK$4.74
HK$7.61
+60.6%
26.3%HK$10.72HK$5.20HK$4.494
Dec ’23HK$4.16
HK$7.22
+73.7%
27.1%HK$10.29HK$4.99HK$4.254

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies